Diamyd Medical AB (publ)
DMYD-B.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$148.45M
Close$
$2.44
139.1% upside
Current Fair Value
139.1% upsideUndervalued by 139.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $148.45 Million |
|---|---|
| Enterprise Value | $-104,726,620.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.51 |
| Beta | 2.29 |
| Outstanding Shares | 150,465,364 |
Return
| Return on Equity | -109.35% |
|---|---|
| Return on Assets | -69.76% |
| Return on Invested Capital | -74.40% |
Valuation & Multiples
| P/E Ratio | -0.5 |
|---|---|
| PEG | -0.27 |
| Price to Sales | - |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | -243.55 |
| Enterprise Value to EBIT | 0.37 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.51 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Diamyd Medical AB (publ)
44 employees
CEO: Anders Essen-Möller Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company ...